Skip to search formSkip to main contentSkip to account menu

TA 5707F

Known as: TA-5707F 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1996
1996
Preparation of controlled release granules of TA-5707F using enteric polymers and ethylcellulose, and their in vivo evaluation.
Two types of multiple controlled release dosage forms, hydroxypropylmethyl cellulose acetyl succinate (HPMC-AS) coated granules… 
1995
1995
In vitro/in vivo evaluation of two series of TA-5707F controlled release matrix tablets prepared with hydroxypropyl methyl cellulose derivatives with entero-soluble or gel-formation properties.
Two series of matrix tablets for the newly developed anti-histaminergic drug, TA-5707F, were prepared: one series with an entero… 
1995
1995
Preparation of controlled release tablets of TA-5707F with wax matrix type and their in vivo evaluation in beagle dogs.
Studies on controlled release dosage forms were conducted by using waxy materials for a newly developed anti-allergy drug, 6… 
1987
1987
Studies on a new antiallergic pyridinecarboxamide TA-5707F and its sodium salt (TA-5707). II. Mechanism of antiallergic action of TA-5707.
Mechanism of the antiallergic action of 6-methyl-N-(1H-tetrazol-5-yl)-2-pyridinecarboxamide (TA-5707F) was studied using the… 
1986
1986
Studies on a new antiallergic pyridinecarboxamide TA-5707F and its sodium salt (TA-5707). I. Inhibition of IgE-induced passive cutaneous anaphylaxis (PCA) in rats.
Effects of TA-5707F [6-methyl-N-(1H-tetrazol-5-yl)-2-pyridinecarboxamide] and its sodium salt (TA-5707) on IgE-induced homologous… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)